Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter M Stadler

Cancer

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Cancer|October 22, 2005
Targeted agents for the treatment of advanced renal cell carcinomaWalter M Stadler
Cancer|August 14, 2002
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaChristopher W Ryan, Nicholas J Vogelzang, Walter M Stadler
Cancer|October 26, 2007
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual reviewKathryn Bylow, Supriya G Mohile, Walter M Stadler, et al.
Cancer|December 19, 2013
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinomaSusan Halabi, Brian Rini, Bernard Escudier, et al.
Cancer|October 5, 2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaApurva A Desai, Nicholas J Vogelzang, Brian I Rini, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|January 16, 2007
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationSupriya G Mohile, Kathryn Bylow, William Dale, et al.
Cancer|May 20, 2008
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinomaEric Jonasch, Walter M Stadler, Ronald M Bukowski, et al.
Cancer|May 10, 2018
Analyzing the clinical actionability of germline pharmacogenomic findings in oncologyRebecca Wellmann, Brittany A Borden, Keith Danahey, et al.
Cancer|August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 ConsortiumDeborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Cancer|October 22, 2005
Targeted agents for the treatment of advanced renal cell carcinomaWalter M Stadler
Cancer|August 14, 2002
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaChristopher W Ryan, Nicholas J Vogelzang, Walter M Stadler
Cancer|October 26, 2007
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual reviewKathryn Bylow, Supriya G Mohile, Walter M Stadler, et al.
Cancer|December 19, 2013
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinomaSusan Halabi, Brian Rini, Bernard Escudier, et al.
Cancer|October 5, 2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaApurva A Desai, Nicholas J Vogelzang, Brian I Rini, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|January 16, 2007
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationSupriya G Mohile, Kathryn Bylow, William Dale, et al.
Cancer|May 20, 2008
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinomaEric Jonasch, Walter M Stadler, Ronald M Bukowski, et al.
Cancer|May 10, 2018
Analyzing the clinical actionability of germline pharmacogenomic findings in oncologyRebecca Wellmann, Brittany A Borden, Keith Danahey, et al.
Cancer|August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 ConsortiumDeborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Pageof 3